Neovascular age-related macular degeneration is a medical condition with active clinical research programs worldwide.

12 total trials for this combination

Showing top 10 of 12 trials

Trials

NCT ID	Title	Status	Phase
NCT03362190	ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)	COMPLETED	PHASE2
NCT04864834	Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration	COMPLETED	PHASE3
NCT03577899	Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)	TERMINATED	PHASE3
NCT04423718	Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye	COMPLETED	PHASE3
NCT05536973	Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]	ACTIVE_NOT_RECRUITING	PHASE2
NCT04757610	OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)	TERMINATED	PHASE3
NCT06223958	Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration	ACTIVE_NOT_RECRUITING	PHASE3
NCT04704921	Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD	ACTIVE_NOT_RECRUITING	—
NCT06495918	Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration	ACTIVE_NOT_RECRUITING	PHASE3
NCT00964795	Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (Wet) Age-related Macular Degeneration (AMD)	COMPLETED	PHASE3

Related Pages

All Neovascular age-related macular degeneration trials All trials in Fullerton, United States